医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MaxiNovel Disclosed the Study Results of Orally Active PD-1/PD-L1 Inhibitors at 2018 AACR

2018年04月18日 AM03:39
このエントリーをはてなブックマークに追加


 

GUANGZHOU, China

MaxiNovel Pharmaceuticals, Inc. presented for the first time the preclinical results of its orally active PD-1/PD-L1 inhibitors either as a single agent or in combo studies. The key findings are as follow:

  • As a single agent in a MC38 model, the MaxiNovel compound (120 mpk) showed similar TGI and ratio of CD8+/Treg to that of aPD-1 Ab (200 μg) reported by BMS group (PLoS One. 2016 Nov 18;11(11): e0167251)
  • In the combination study in a MC38 model, the MaxiNovel compound (30 mpk) demonstrated statistically significant combo efficacy with Celebrex, Cisplatin, Epacadostat and aCTLA-4 Ab.
  • In the combination study in a 4T1 model, the MaxiNovel compound (30 mpk) in combination with aCTLA-4 Ab had similar survival ratio as that of aPD-1Ab/aCTLA-4 Ab combination reported by researchers from Australia and US (Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11774-9)

“While IO combination is the industrial trend, the ultimate success will be dependent on the safety of various combinations,” commented Dr. David Moore, MaxiNovel’s SVP of DMPK and Drug Safety. “These orally active small molecule PD-1/PD-L1 inhibitors will provide more flexibility for dose and safety adjustment in the combination with various drugs. Maxinovel has demonstrated statistically significant efficacy of two-component combination with excellent safety in various tumor models. Future goals will be to conduct three, four or even more component combinations, perhaps in a single oral pill.”

Dr. Zujun Li, the Clinical Associate Professor of Medicine at New York University and the PI for immunotherapy clinical trials echoed “we are encouraged by the study results and excited about the small molecules targeting PD-1/PD-L1 pathway. We are looking forward to the orally active drugs to be added to today’s antibody only therapy.”

About MaxiNovel Pharmaceuticals, Inc:

Maxinovel Pharmaceuticals, Inc. is a biotech company focusing on the discovery and development of Immuno-oncology therapy and targeted therapy. It will use its orally active Immuno-oncology product platform to bring effective combo product of multi-components in a single oral pill to the patients worldwide. For more info: www.maxinovel.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20180417006491/en/

CONTACT

MaxiNovel Pharmaceuticals, Inc.
Ms. Pingjing Zhang
pjzhang@maxinovel.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease